Modifiedpriority healthPolicy N/A

Chelation Therapy Coverage Criteria

Establishes Priority Health coverage criteria, applicable diagnoses, documentation, coding, and prior authorization considerations for chelation therapy; applies to Priority Health members and providers delivering care under covered plans.

Policy Summary

Payerpriority health

PolicyChelation Therapy Coverage Criteria

Policy CodePolicy N/A

Change TypeMaterial — added non-covered conditions

Effective DateMar 1, 2026

Next Review DateN/A

Key ActionSubmit prior authorization with documentation demonstrating medical necessity for chelation therapy; individual case review may be required for exceptions.

SourceLink

POLICY UPDATE CHANGES

Added additional non-covered conditions for chelation therapy.

New Policy Scope section was added.

New FDA/Regulatory section was added.

New Medical/Professional Society Guidelines section was added.

Policy structure clarified.

6+medically necessary diagnoses

4example non-covered conditions

5CPT/HCPCS codes listed

MultipleICD-10 groups

Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.

Coverage Criteria for Chelation Therapy

Medically Necessary Indications

Chelation therapy is medically necessary when used to treat ALL of the following diagnoses as listed:

Medically necessary diagnoses

Included diagnoses: a. Biliary cirrhosis; b. Cooley's anemia; c. Cystinuria; d. Heavy metal poisoning (e.g., arsenic, copper, gold, iron, lead, mercury); e. Wilson's disease; f. Patients who have iron overload secondary to multiple blood transfusions (e.g., sickle cell anemia)
Each listed diagnosis is an acceptable indication

Not Medically Necessary

Chelation therapy is considered not medically necessary when used to treat the following conditions:

Not medically necessary

Examples: Autism Spectrum Disorders; Cardiovascular disease (including atherosclerosis, coronary artery disease); Neurodegenerative disorders (Alzheimer's disease or other dementias); Stroke
List is not exhaustive

Coverage for chelation therapy is contingent on the member's specific benefits and the applicable plan documents. Group-specific policy or state‑mandated plan documents will supersede this medical policy when applicable. For self‑funded (ASO), individual, HMO/EPO, POS, PPO, Medicare, and Medicaid/Healthy Michigan Plan products, providers should consult the applicable plan or product documents for final coverage determinations; when discrepancies exist, the plan or program rules govern. Providers seeking prior authorization must follow the procedures in the Priority Health Provider Manual and submit documentation demonstrating medical necessity when prior authorization is required.

The literature and guideline commentaries flag the use of chelation therapy for Autism Spectrum Disorder and for treatment of alleged mercury poisoning without appropriate diagnostic evaluation as unsupported and potentially harmful. Choosing Wisely and specialty toxicology guidance specifically caution against chelation except for documented metal intoxication diagnosed by validated testing, and reviews of autism-related chelation trials note poor quality evidence and safety concerns.

Use of chelation therapy to treat Autism Spectrum Disorder is not supported by quality evidence and is considered not medically necessary. Professional organizations and systematic reviews advise against routine testing or chelation for autistic behaviors; published case reports and series also document serious adverse events associated with inappropriate chelation in children.

Chelation therapy for atherosclerotic cardiovascular disease and for neurodegenerative disorders (including Alzheimer's disease) is not proven to improve clinical outcomes in routine practice and is considered not medically necessary. Large trials and systematic reviews (including TACT and TACT2 and multiple reviews) did not demonstrate consistent benefit across populations; some subgroup findings were not replicated and more high‑quality evidence is required before routine use can be recommended.

Sources cited in this policy identify chelation for Autism Spectrum Disorder and for unproven claims of mercury poisoning as unsupported and potentially inappropriate. Toxicology and clinical practice guidance emphasize that chelating agents should be reserved for documented heavy metal intoxication confirmed by validated biological testing, and that use for unverified mercury exposure or other non‑evidence‑based indications may prompt denial of coverage or safety concerns.

Relevant Coding

ICD-10 Codes that may support medical necessityICD-10

D56.0 - D56.9	Thalassemia
D57.00 - D57.819	Sickle-cell disorders
E72.00 - E72.09	Disorders of amino-acid transport
E83.00 - E83.09	Disorders of copper metabolism
E83.10 - E83.19	Disorders of iron metabolism
E83.52	Hypercalcemia
K74.3	Primary biliary cirrhosis
K74.4	Secondary biliary cirrhosis
K74.5	Biliary cirrhosis, unspecified
T56.0x1A - T56.0x4S	Toxic effects of lead and its compounds

1–10 of 19

1/2

CPT/HCPCS CodesHCPCS

J0470	Injection, dimercaprol, per 100 mg.
J0600	Injection, edetate calcium disodium, up to 1000 mg.
J0895	Injection, deferoxamine mesylate, 500 mg.
J3520	Edetate disodium, per 150 mg (not covered for Medicaid)
S9355	Home infusion therapy, chelation therapy; administrative services, professional pharmacy services, care coordination, and all necessary supplies and equipment (drugs and nursing visits coded separately), per diem requires prior auth

Typical infusion series — inv-10: Typical infusion series

Typical series lengthApproximately 30 intravenous infusions (delivered weekly or biweekly); individual protocols may vary (example: 40 infusions in TACT2).

EDTA dose exampleTypical protocol described as 3 g disodium EDTA per infusion delivered in 500–1000 mL normal saline over 1.5–3 hours.

Adjunctive agents usedConcomitant administration often includes ascorbic acid, B‑vitamins, heparin, and minerals (magnesium, copper, zinc, selenium, manganese).

Maintenance scheduleAfter initial series, therapy may be followed by a less‑frequent maintenance schedule as clinically indicated.

Provider Actions, Prior Authorization & Documentation

Step Therapy

Stepwise chelation for iron overload

For iron overload (transfusional or secondary), clinicians should follow a stepwise approach using guideline‑recommended iron chelators. Initiation, selection, and modification of therapy should be based on established indications, iron burden measures, tolerability, and response. Prior authorization and documentation requirements still apply for individual agents or combination regimens.

Preferred agents: deferoxamine, deferiprone, deferasirox (select according to age, formulation availability, and adverse-effect profile).
Start with monotherapy using an evidence‑based agent appropriate for the patient; escalate to alternative single agents if ineffective or not tolerated.
Consider combination regimens (e.g., deferasirox + deferoxamine or deferiprone + deferoxamine) for patients with inadequate response to monotherapy or severe iron burden, supported by clinical evidence.
Document baseline iron burden (e.g., serum ferritin trends, liver iron concentration by MRI) and clinical rationale for switching or adding agents.
Monitor for drug-specific adverse effects (e.g., agranulocytosis with deferiprone; renal/hepatic toxicity with deferasirox; infusion‑related issues with deferoxamine) and provide laboratory surveillance per product labeling.
Provide evidence of prior trials of guideline‑recommended therapy when requesting individual case review or authorization for combination therapy or off‑label regimens.

Definitions and Protocols

Chelation therapy — inv-20: Chelation therapy

DefinitionAdministration of a chelating agent (e.g., EDTA, DMSA, DMPS) to bind heavy metals and facilitate urinary excretion; often involves repeated IV infusions with supportive agents.

Typical deliveryRepeated intravenous administration of chelating agents (weekly or biweekly in many protocols).

Primary indicationProven effective for documented heavy metal intoxication and specific diagnoses such as Wilson's disease and transfusional iron overload.

Evidence limitsNot shown to improve objective outcomes for autism, cardiovascular disease, or neurodegenerative conditions (e.g., Alzheimer’s) per cited reviews and guidelines.

Typical EDTA protocol — inv-21: Typical EDTA protocol

EDTA protocol summary

Background and Evidence Summary

Chelation refers to administration of agents such as EDTA, DMSA, or DMPS to bind metals and enhance urinary excretion. A commonly cited EDTA regimen involves repeated intravenous infusions—typically a series of approximately 30 infusions of 3 g disodium EDTA with adjunctive vitamins, minerals, and supportive agents delivered over 1.5–3 hours in 500–1000 mL saline, often on a weekly or biweekly schedule. Evidence supports chelation for documented heavy metal intoxication and selected hematologic or genetic conditions that cause iron or copper overload, whereas proposed uses outside these indications lack robust evidence.